Op-ed: The 1 way pharma can get on Trump's good side

The time has come for drug companies to get serious about making a deal with the government over high drug prices, according to Jake Novak, a senior columnist for CNBC.

During his Wednesday press conference, President-elect Donald Trump criticized drug companies for leaving the country, yet still selling drugs here — much like he's called out automotive companies for moving production outside of the U.S., said Mr. Novak in a column for CNBC.

By looking at the pharmaceutical industry through a manufacturing-based lens, Mr. Trump opened "the door to a whole new way of negotiating with the drug companies," wrote Mr. Novak.

Now, drugmakers have the option to follow suit with companies like Ford or Fiat Chrysler and get on Mr. Trump's good side by promising to bring back — or save — American jobs in drug manufacturing plants still located in the U.S.

"If the Big Pharma CEOs are smart, they should start thinking about doing that right away," said Mr. Novak. "Trump wants drug prices to go down and he has the power to make life very unpleasant for the companies that don't comply."

More articles on supply chain:

AbbVie CEO pledges to rein in price hikes
National Cancer Institute unveils ambitious program to hasten drug research
Abuse-deterrent opioid primary cause of heroin overdose boom, researchers find


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars